Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system
FAERS analysis revealed new AE signals (sepsis, colitis) for Bortezomib and highlighted Carfilzomib's heightened cardiac and renal risks compared to Bortezomib. Balancing PIs' benefits and risks is crucial for clinical decision-making.
Authors
- Ting Ye
- Dongdong Yu (ORCID: https://orcid.org/0000-0003-2759-7647)
- Dawei Liu (ORCID: https://orcid.org/0000-0003-1911-9207)
- Xiaoyu Cheng (ORCID: https://orcid.org/0009-0003-2684-5909)
- Wenjun Xu (ORCID: https://orcid.org/0000-0003-4887-3372)
- Tong Liu (ORCID: https://orcid.org/0000-0003-0482-0738)
- Ting Cheng (ORCID: https://orcid.org/0000-0003-0779-4272)
- Shanshan Cai (ORCID: https://orcid.org/0000-0003-0117-5171)
- Yuxiang Guan (ORCID: https://orcid.org/0000-0002-8003-6091)
- Jinzhi Dai
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Anhui University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1080/14740338.2024.2393275
- Citations
- 1
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.35